Werewolf Therapeutics Announces Promising New Development Candidate, WTX-921, a first-of-its-kind IL-10 INDUKINE™ Molecule for Inflammatory Diseases
Werewolf Therapeutics, Inc. (HOWL)
Company Research
Source: GlobeNewswire
WATERTOWN, Mass., Oct. 31, 2024 (GLOBE NEWSWIRE) -- Werewolf Therapeutics, Inc. (the “Company” or “Werewolf”) (Nasdaq: HOWL), an innovative biopharmaceutical company pioneering the development of conditionally activated therapeutics engineered to stimulate the body’s immune system for the treatment of cancer and other immune-mediated conditions, today announced the addition of WTX-921, a novel IL-10 INDUKINE development candidate for Inflammatory Bowel Disease (IBD) and potentially other inflammatory diseases, to the Company’s pipeline. This pipeline expansion underscores the transformative promise of the Werewolf’s PREDATOR® platform to apply the INDUKINE approach to therapeutic areas outside of oncology. Werewolf’s INDUKINE molecules have shown promising safety and efficacy results in ongoing oncology clinical trials. Their validated approach entails the identification of novel protease-cleavable linkers that enable the conditional activation of wild-type cytokines, optimizing
Show less
Read more
Impact Snapshot
Event Time:
HOWL
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
HOWL alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
HOWL alerts
High impacting Werewolf Therapeutics, Inc. news events
Weekly update
A roundup of the hottest topics
HOWL
News
- Werewolf Therapeutics GAAP EPS of -$0.38 beats by $0.07 Nov. 08, 2024 2:25 AM ET By: Manshi Mamtora , CFA [Seeking Alpha]Seeking Alpha
- Werewolf Therapeutics Presents Preclinical and Clinical Data at the Society for Immunotherapy of Cancer’s (SITC) 39th Annual MeetingGlobeNewswire
- Werewolf Therapeutics Reports Third Quarter 2024 Financial Results and Provides Business UpdateGlobeNewswire
- Werewolf Therapeutics to Present Posters at the Society for Immunotherapy of Cancer’s (SITC) 39th Annual MeetingGlobeNewswire
- Werewolf Therapeutics to Participate in the H.C. Wainwright 26th Annual Global Investment ConferenceGlobeNewswire
HOWL
Earnings
- 11/7/24 - Beat
HOWL
Sec Filings
- 11/14/24 - Form SC
- 11/14/24 - Form SC
- 11/13/24 - Form SC
- HOWL's page on the SEC website